Fundació Clínic per a la recerca Biomèdica (FCRB)

Presentation of the Organisation
FCRB is the entity managing the research activities of Hospital Clínic i Provincial de Barcelona. FCRB has a very high scientific production. In 2006 alone, FCRB published 561 original articles, of which many were collaborative studies, including a large number of projects financed under EU Framework Programme. The actual impact factor of each article is 4.60. The global impact factor for the journals where the abovementioned articles have appeared is 2,582 points.
The Clinical Pharmacology Department includes a Clinical Trials Unit (CTU) devoted to the support of Academic clinical research. CTU tasks include trial co-ordination, protocol and CRF design, submission to Ethics Committees and Authorities, monitoring, data management, statistical analysis and reporting. The CTU is involved in the conducting and co-ordination of more than 20 academic multicentre clinical trials, including some NIH-sponsored studies. It will be in charge of managing the FOCUS project contribution of FCRB.

Key people involved
Joan-Albert Arnaiz, MD: Head of the CTU, with more than 10 years of experience in the co-ordination of clinical trials, is Physician and Clinical Pharmacologist His main activities entail the co-ordination of a Hospital-based Clinical Trials Unit devoted to the design, monitoring, analysis and reporting of academic phase II-IV multicenter clinical trials in different fields.
Xavier Carné, MD: Head of the Clinical Pharmacology Department at HCPB, Barcelona and Professor of Pharmacology at the University of Barcelona. Chairman of the Drug Evaluation Commission at the Spanish Medicines Agency (AEMPS), is a well known expert in European clinical research, bioethics and drug regulatory issues. He is member of the ECRIN network committee.
Sara Varea, BSc: Senior Clinical Research Manager at CTU with more than 10 years of experience in clinical trials management. She has been involved in coordination of national and international non-commercial trials. She will act as an intermediary between the sponsor and Spanish Competent Authorities and researchers. She will be also coordinating FOCUS study monitoring in Spain.
Further Information

Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Istituto di Richerche Farmacologiche Mario Negri (IRFMN)
Instituto DAMIC (DAMIC)
Fundació Clínic per a la recerca Biomèdica (FCRB)
Federación Argentina de Cardiología (FAC)
World Heart Federation (WHF)
Instituto de Salud Carlos III (ISCIII